Canada unveils new labeling initiative to enhance drug safety
Canada health minister Leona Aglukkaq said that millions of Canadians rely on drugs to maintain and improve their health and vague labeling carries some risks. The government will
Ionis Pharmaceuticals has entered a licence agreement granting global pharmaceutical company Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.
Targeting Her2-positive breast cancer, ARX788 is developed by the clinical stage biopharmaceutical company Ambrx as site-specific ADC. According to the deal, both the companies will continue developing the
The collaboration will integrate Genmab’s high-affinity fully human antibody targeting CD25, HuMax-TAC, with ADC’s PBD-based warhead and linker technology for the devlopment of new product. Genmab chief executive